Galmed Pharmaceuticals Ltd. 宣布,已调整对Colospan Ltd.的收购条款,旨在优先推进CG-100在欧洲的商业化进程,并保护公司股东价值。此次收购现已完成。新的条款结构反映了公司战略重点的调整,确保核心资产的价值最大化,同时为未来的市场拓展奠定坚实基础。
Galmed Pharmaceuticals Ltd. 宣布,已调整对Colospan Ltd.的收购条款,旨在优先推进CG-100在欧洲的商业化进程,并保护公司股东价值。此次收购现已完成。新的条款结构反映了公司战略重点的调整,确保核心资产的价值最大化,同时为未来的市场拓展奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.